Effectiveness of crizotinib versus entrectinib in <i>ROS1</i> -positive non-small-cell lung cancer using clinical and real-world data
Effectiveness of crizotinib versus entrectinib in <i>ROS1</i> -positive non-small-cell lung cancer using clinical and real-world data is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Effectiveness of crizotinib versus entrectinib in <i>ROS1</i> -positive non-small-cell lung cancer using clinical and real-world data have?
Effectiveness of crizotinib versus entrectinib in <i>ROS1</i> -positive non-small-cell lung cancer using clinical and real-world data has 23 citations in the OpenAlex counts ScholarIQ stores.
When was Effectiveness of crizotinib versus entrectinib in <i>ROS1</i> -positive non-small-cell lung cancer using clinical and real-world data published?
Effectiveness of crizotinib versus entrectinib in <i>ROS1</i> -positive non-small-cell lung cancer using clinical and real-world data has 2022 year in the ScholarIQ index.
What is the open-access status of Effectiveness of crizotinib versus entrectinib in <i>ROS1</i> -positive non-small-cell lung cancer using clinical and real-world data?
Effectiveness of crizotinib versus entrectinib in <i>ROS1</i> -positive non-small-cell lung cancer using clinical and real-world data has hybrid oa status in the ScholarIQ index.
What is the DOI of Effectiveness of crizotinib versus entrectinib in <i>ROS1</i> -positive non-small-cell lung cancer using clinical and real-world data?
The DOI for Effectiveness of crizotinib versus entrectinib in <i>ROS1</i> -positive non-small-cell lung cancer using clinical and real-world data is on the source record.
What is the PMID of Effectiveness of crizotinib versus entrectinib in <i>ROS1</i> -positive non-small-cell lung cancer using clinical and real-world data?
The PMID for Effectiveness of crizotinib versus entrectinib in <i>ROS1</i> -positive non-small-cell lung cancer using clinical and real-world data is on the source record.
What is the OpenAlex record for Effectiveness of crizotinib versus entrectinib in <i>ROS1</i> -positive non-small-cell lung cancer using clinical and real-world data?
The OpenAlex for Effectiveness of crizotinib versus entrectinib in <i>ROS1</i> -positive non-small-cell lung cancer using clinical and real-world data is on the source record.